Efficacy of PLD-118, a novel inhibitor of Candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 10, 2004, Pages 3959-3967

  Petraitis, Vidmantas ^a,b   Petraitiene, Ruta ^a   Kelaher, Amy M ^a   Sarafandi, Alia A ^a   Sein, Tin ^a   Mickiene, Diana ^a   Bacher, John ^c   Groll, Andreas H ^a,d   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 METHYLENECYCLOPENTANECARBOXYLIC ACID; AMPHOTERICIN B DEOXYCHOLATE; FLUCONAZOLE; GENTAMICIN; ISOLEUCINE TRANSFER RNA LIGASE; METHYLPREDNISOLONE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; CANDIDA ALBICANS; CANDIDIASIS; CELL STRUCTURE; CLEARANCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; ESOPHAGUS; ESOPHAGUS DISEASE; FEMALE; FUNGUS GROWTH; FUNGUS ISOLATION; IMMUNE DEFICIENCY; MINIMUM INHIBITORY CONCENTRATION; MOUTH INFECTION; NONHUMAN; OROPHARYNX; PHARYNGITIS; PLASMA CLEARANCE; PRIORITY JOURNAL; RABBIT; TONGUE;

ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CANDIDA ALBICANS; CANDIDIASIS; CANDIDIASIS, ORAL; CYCLOLEUCINE; DRUG RESISTANCE, FUNGAL; ENZYME INHIBITORS; ESOPHAGEAL DISEASES; FEMALE; FLUCONAZOLE; HALF-LIFE; IMMUNOSUPPRESSION; ISOLEUCINE-TRNA LIGASE; RABBITS;

EID: 4644234808     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.10.3959-3967.2004     Document Type: Article

References (33)

1. Aoyama, Y., M. Kudo, K. Asai, K. Okonogi, T. Horiuchi, O. Gotoh, and Y. Yoshida. 2000. Emergence of fluconazole-resistant sterol 14-demethylase P450 (CYP51) in Candida albicans is a model demonstrating the diversification mechanism of P450. Arch. Biochem. Biophys. 379:170-171.
2. Arathoon, E. G., E. Gotuzzo, L. M. Noriega, R. S. Berman, M. J. DiNubile, and C. A. Sable. 2002. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. 46:451-457.
3. Asai, K., N. Tsuchimori, K. Okonogi, J. R. Perfect, O. Gotoh, and Y. Yoshida. 1999. Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450. Antimicrob. Agents Chemother. 43:1163-1169.
4. Barbaro, G., G. Barbarini, W. Calderon, B. Grisorio, P. Alcini, and G. Di Lorenzo. 1996. Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Gastroenterology 111:1169-1177.
5. Brassinne, C., C. Laduron, A. Coune, J. P. Sculier, C. Hollaert, N. Collette, and F. Meunier. 1987. High-performance liquid chromatographic determination of amphotericin B in human serum. J. Chromatogr. 7:401-407.
6. Cartledge, J. D., J. Midgley, and B. G. Gazzard. 1997. Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis. AIDS 11:1839-1844.
7. Chiou, C. C., A. H. Groll, C. E. Gonzalez, D. Callender, D. Venzon, P.A. Pizzo, L. Wood, and T. J. Walsh. 2000. Esophageal candidiasis in pediatric acquired immunodeficiency syndrome: clinical manifestations and risk factors. Pediatr. Infect. Dis. J. 19:729-734.
8. Chiou, C. C., A. H. Groll, N. Mavrogiorgos, L. V. Wood, and T. J. Walsh. 2002. Esophageal candidiasis in human immunodeficiency virus-infected pediatric patients after the introduction of highly active antiretroviral therapy. Pediatr. Infect. Dis. J. 21:388-392.
9. Cross, E. W., S. Park, and D. S. Perlin. 2000. Cross-resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis. Microbiol. Drug Resist. 6:155-161.
10. Fung-Tomc, J. C., T. C. White, B. Minassian, E. Huczko, and D. P. Bonner. 1999. In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole. Diagn. Microbiol. Infect. Dis. 35:163-167.
11. Ghannoum, M. A., and B. Elewski. 1999. Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine. Clin. Diagn. Lab. Immunol. 6:921-923.
12. Graybill, J. R. 2000. Changing strategies for treatment of systemic mycoses. Braz. J. Infect. Dis. 4:47-54.
13. Haberland-Carrodeguas, C. C. M. Allen, F. M. Beck, W. J. Buesching, S. L. Koletar, and P. Sundstrom. 2002. Prevalence of fluconazole-resistant strains of Candida albicans in otherwise healthy outpatients. J. Oral Pathol. Med. 31:99-105.
14. Marr, K. A., T. C. White, J. A. van Burik, and R. A. Bowden. 1997. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin. Infect. Dis. 25:908-910.
15. Masia Canuto, M., F. Gutierrez Rodero, V. Ortiz de la Tabla Ducasse, I. Hernandez Aguado, C. Martin Gonzalez, A. Sanchez Sevillano, and A. Martin Hidalgo. 2000. Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients. Eur. J. Clin. Microbiol. Infect. Dis. 19:593-601.
16. Mittendorf, J., F. Kunisch, M. Matzke, H.-C. Militzer, A. Schmidt, and W. Schönfeld. 2003. Novel antifungal-amino acids: synthesis and activity against Candida albicans. Bioorg. Med. Chem. Lett. 13:433-436.
17. Morschhauser, J. 2002. The genetic basis of fluconazole resistance development in Candida albicans. Biochim. Biophys. Acta 1587:240-248.
18. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
19. National Research Council Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
20. Petraitiene, R., V. Petraitis, A. H. Groll, M. Candelario, T. Sein, A. Bell, C. A. Lyman, C. L. McMillian, J. Bacher, and T. J. Walsh. 1999. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob. Agents Chemother. 43:2148-2155.
21. Petraitis, V., R. Petraitiene, A. H. Groll, T. Sein, R. L. Schaufele, C. A. Lyman, A. Francesconi, J. Bacher, S. C. Piscitelli, and T. J. Walsh. 2001. Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. 45:471-479.
22. Revankar, S. G., O. P. Dib, W. R. Kirkpatrick, R. K. McAtee, A. W. Fothergill, M. G. Rinaldi, S. W. Redding, and T. F. Patterson. 1998. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 26:960-963.
23. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
24. Roy, M. J., and T. J. Walsh. 1992. Histopathological and immunohistochemical changes in gut-associated lymphoid tissues following treatment of rabbits with dexamethasone. Lab. Investig. 64:437-443.
25. Ruhnke, M., A. Adler, and F. M. Muller. 2000. Clearance of a fluconazole-resistant Candida albicans strain after switching antifungal therapy and initiation of triple therapy for HIV infection. Clin. Microbiol. Infect. 6:220-223.
26. Shargel, L., and A. B. C. Yu. 1993. Applied biopharmaceutics and pharmacokinetics, p. 47-61. Appleton & Lange, Norwalk, Conn.
27. Villanueva, A., E. Gotuzzo, E. G. Arathoon, L. M. Noriega, N. A. Kartsonis, R. J. Lupinacci, J. M. Smietana, M. J. DiNubile, and C. A. Sable. 2002. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. 113:294-299.
28. Walsh, T. J., C. E. Gonzalez, S. Piscitelli, J. D. Bacher, J. Peter, R. Torres, D. Shetti, V. Katsov, K. Kligys, and C. A. Lyman. 2000. Correlation between in vitro and in vivo antifungal activity in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. J. Clin. Microbiol. 38:2369-2373.
29. Walsh, T. J., C. McEntee, and D. M. Dixon. 1987. Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans. J. Clin. Microbiol. 25:931-932.
30. Walsh, T. J., J. Bacher, and P. A. Pizzo. 1988. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Lab. Anim. Med. 38:467-470.
31. Wilcox, C. M., R. F. Straub, L. N. Alexander, and W. S. Clark. 1996. Etiology of esophageal disease in human immunodeficiency virus-infected patients who fail antifungal therapy. Am. J. Med. 101:599-604.
32. Ziegelbauer, K., P. Babczinski, and W. Schonfeld. 1998. Molecular mode of action of the antifungal beta-amino acid BAY 10-8888. Antimicrob. Agents Chemother. 42:2197-2205.
33. Ziegelbauer, K. 1998. Decreased accumulation or increased isoleucyl-tRNA synthetase activity confers resistance to the cyclic beta-amino acid BAY 10-8888 in Candida albicans and Candida tropicalis. Antimicrob. Agents Chemother. 42:1581-1586.